Highlights•Human epidermal growth factor receptor 2 (HER2) alterations lead to poor
prognosis in non-small-cell lung cancer (NSCLC).•Identifying HER2 alterations is pivotal to …

Sensitivity to Her2-directed therapies is complex and involves expression not only of Her2
but also of other epidermal growth factor receptor (EGFR) family members, their ligands, and …

Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown
to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in …

Oncogenic driver mutations have emerged as major treatment targets for molecular
therapies in a variety of cancers. HER2 positivity has been well-studied in breast cancer, but …

PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of
breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC) …

Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …

Objectives While novel anti-human epidermal growth factor receptor 2 (HER2) agents have
recently been developed, no definite criteria have been proposed as indications for the use …

Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently
approved for breast, gastric, and gastroesophageal cancers overexpressing the HER2 …

In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led
to the definition of different clinical entities with different therapeutic opportunities, as …

PURPOSE HER2 exon 20 insertions and point mutations are oncogenic drivers found in 1%-
2% of patients with non–small-cell lung cancer (NSCLC). No targeted therapy is approved …